pharmaceutical
Fed likely to keep rates steady as it awaits Trump economic plan
February 1, 2017 by admin · Leave a Comment
By Lindsay Dunsmuir WASHINGTON (Reuters) – The U.S. Federal Reserve is expected to keep interest rates unchanged on Wednesday in its first policy decision since President Donald Trump took office, as the central bank awaits greater clarity on his economic policies. Trump has promised a large infrastructure spending program, tax cuts, a rollback of regulations and a renegotiation of trade deals but has offered few details or a timeline for their roll out…
See the original post:
Fed likely to keep rates steady as it awaits Trump economic plan
pharmaceutical
Trump pushes drugmakers for lower prices, more U.S. production
February 1, 2017 by creative · Leave a Comment
WASHINGTON/LOS ANGELES (Reuters) – U.S. President Donald Trump in a meeting on Tuesday with pharmaceutical executives called on them to manufacture more of their drugs in the United States and cut prices, while vowing to speed approval …
The rest is here:
Trump pushes drugmakers for lower prices, more U.S. production
pharmaceutical
Fed’s Kaplan urges ‘slow, gradual, careful’ approach on rates
July 13, 2016 by elegant · Leave a Comment
Global headwinds are undercutting the Federal Reserve's efforts to boost the U.S. economy, making low interest rates not nearly as stimulative as they were when the rest of the world economy was growing faster, a top Fed official said on Wednesday. A “slow, gradual, careful” approach to raising interest rates is therefore appropriate as the U.S. central bank deals with this new world of slower growth, Dallas Fed President Robert Kaplan said in a …
Original post:
Fed’s Kaplan urges ‘slow, gradual, careful’ approach on rates
pharmaceutical
Teva says Allergan deal to close ‘any time’, expects U.S. antitrust clearance
July 13, 2016 by creative · Leave a Comment
NEW YORK/TEL AVIV (Reuters) – Teva Pharmaceutical Industries Ltd said on Wednesday it expected its $40 billion deal to buy Allergan Plc's generics business to close “at any time,” even as the companies extended the deadline for completing the transaction to October to allow more time for the U.S. antitrust review. “We …
See the original post here:
Teva says Allergan deal to close ‘any time’, expects U.S. antitrust clearance